Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared a post on LinkedIn:
“I’m so honored to present this study on patient awareness of HER2-low breast cancer, led by amazing Rebecca Previs, Labcorp and Outcomes4Me SABCS24.
We deployed a six-month patient-centric educational campaign around HER2 testing and HER2-low mBC.
A pre-campaign survey showed
- 41.9% of patients with a known HER2 status were not at all aware or not very aware of the HER2-low classification.
- 51% with HER2-negative on recent testing did not recall their oncologist discussing HER2-low as a possibility
Patient awareness gaps exist around relevant biomarker testing.
After engaging with the campaign, 60.9% with unknown HER2 status felt very or somewhat likely to talk to their oncologist about testing for HER2-low.”
